Dec. 10, 2007
Audio Journal of Oncology, December 9th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta Interleukin-2 For Acute Myeloid Leukemia In First Remission? JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY GEORGE CANELLOS, Dana-Farber Cancer Institute REFERENCE: ABSTRACT 157, ASH 2007 New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where does dasatinib stand as an emerging CML therapy? Richard Stone of the Dana-Farber Cancer Institute in Boston explained all to Derek Thorne, while George Canellos, of the same institute, gave another perspective on the data.